Novel chalcone derivative for cancer treatment

Researchers of the Medical University of Vienna have identified highly
active synthetic chalcones derived from the chalcone scaffold. These
cytotoxic compounds were found and developed by modifying the
chalcone lead structure concurrent with in vitro tests to evaluate their
cytotoxic potential in different cancer cell lines. Compounds were
thoroughly tested regarding their efficacy in inhibiting proliferation and
viability in cancer cell lines of the hematopoietic system. The combination of the new chalcone compound with the targeting agents, Idelalisib and Ibrutinib, which are novel compounds in the treatment of hematological malignancies, displayed higher cytotoxicity on CLL cells than Idelalisib and Ibrutinib alone.

Further information: PDF

Wissenstransferzentrum Ost (WTZ Ost)
Phone: +43 1 401 60 25 202

Contact
Dr. Michael Hoschitz

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.